In this Comment, we provide a strategic framework for what could and should be measured, across four domains, to optimize standards of care for multidisciplinary models of care in nonalcoholic fatty liver disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lazarus, J. V. et al. Defining comprehensive models of care for NAFLD. Nat. Rev. Gastroenterol. Hepatol. 18, 717–729 (2021).
Karlsen, T. H. et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399, 61–116 (2022).
Kumar, S. et al. Multidisciplinary clinic models: a paradigm of care for management of NAFLD. Hepatology 74, 3472–3478 (2021).
Zoncapè, M., Liguori, A. & Tsochatzis, E. A. Multi-disciplinary clinic models for the management of non-alcoholic fatty liver disease. Hepatobiliary Surg. Nutr. 11, 586–591 (2022).
McPherson, S. et al. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterol. Hepatol. 7, 755–769 (2022).
Carrieri, P. et al. Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes. Liver Int. 42, 984–994 (2022).
Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J. Hepatol. 71, 371–378 (2019).
Dillon, J. F. et al. Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care. J. Hepatol. 71, 699–706 (2019).
Neilson, L. J. et al. Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease. Frontline Gastroenterol. 12, 578–585 (2021).
Allen, A. M., Lazarus, J. V. & Younossi, Z. M. Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties. J. Hepatol. https://doi.org/10.1016/j.jhep.2023.01.026 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.M.A. has received grant support to her institution from the National Institutes of Health (NIH) (DK128127), Novo Nordisk, Pfizer and Target Pharma and has participated in advisory boards for Novo Nordisk, outside of the submitted work. Z.M.Y. has received consulting fees from Gilead, Intercept, Siemens, Novo Nordisk, Madrigal, Merck, Quest and Bristol Myers Squibb, outside of the submitted work. E.A.T. has participated in advisory boards for and received consulting fees from Boehringer, Pfizer and Novo Nordisk and has given lectures for Novo Nordisk and Dr Falk, outside of the submitted work. S.Z-S. has given presentations for and received meeting and/or travel support from AbbVie, outside of the submitted work. K.C. has received grant support to his institution from Echosens, Inventiva, Poxel, Novo, Labcorp and Zydus, consulting fees from BMS, Lilly, Madrigal, Merck, Myovant, Novo Nordisk, Prosciento, Quest, Sagimet, Sonic Incytes and Terns and other support from Echosens, Inventiva, Poxel, Labcorp and Zydus, outside of the submitted work. J.V.L. acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD and Roche Diagnostics to his institution, speaker fees from Intercept, Janssen, Novo Nordisk and ViiV and consulting fees from Novavax, outside of the submitted work. J.V.L. also acknowledges support to ISGlobal from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033 and the “Generalitat de Catalunya” through the CERCA programme, outside of the submitted work. W.A. and J.P.A. declare no competing interests.
Rights and permissions
About this article
Cite this article
Allen, A.M., Younossi, Z.M., Tsochatzis, E.A. et al. Measuring NAFLD models of care. Nat Rev Gastroenterol Hepatol 20, 626–627 (2023). https://doi.org/10.1038/s41575-023-00798-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00798-9
